BTMD · Biote Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.94M | - | $47.96M | $48.86M | $48.99M | - | $51.38M | $49.17M | $46.80M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $27.79M | - | $26.15M | $24.22M | $26.69M | - | $24.03M | $27.65M | $23.01M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $980.0K | - | - | - | $857.0K | - | $200.0K | $200.0K | $750.0K | - |
| Operating Income | $3.17M | - | $8.27M | $10.77M | $9.69M | - | $12.18M | $6.23M | $10.43M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $662.0K | - | ($765.0K) | $2.15M | $1.62M | - | $3.20M | $180.0K | $2.49M | - |
| Net Income | $2.28M | - | $8.19M | $3.19M | $13.72M | - | $10.70M | ($6.32M) | ($2.07M) | - |
| EPS - Basic | $0.07 | - | $0.26 | $0.10 | $0.44 | - | $0.34 | ($0.19) | ($0.06) | - |
| EPS - Diluted | $0.06 | - | $0.22 | $0.10 | $0.37 | - | $0.33 | ($0.19) | ($0.06) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.32M | $24.12M | $28.05M | $19.60M | $41.70M | $39.34M | $38.23M | $26.42M | $78.79M | $89.00M |
| Accounts Receivable | $7.40M | $6.87M | $7.97M | $9.07M | $7.76M | $7.63M | $8.49M | $7.70M | $8.02M | $6.81M |
| Inventory | $19.88M | $19.06M | $16.45M | $12.13M | $13.45M | $14.85M | $16.20M | $19.21M | $18.92M | $17.31M |
| Accounts Payable | $8.24M | $6.83M | $4.36M | $3.86M | $3.33M | $5.81M | $4.37M | $5.79M | $4.20M | $4.16M |
| Current Assets | $36.36M | $54.67M | $57.12M | $49.50M | $68.68M | $68.13M | $69.98M | $61.77M | $114.36M | $122.34M |
| Total Assets | $89.03M | $107.61M | $111.32M | $104.80M | $123.38M | $122.37M | $101.25M | $92.90M | $160.11M | $155.29M |
| Current Liabilities | $28.23M | $44.99M | $56.31M | $50.54M | $48.47M | $51.51M | $46.51M | $46.27M | $24.06M | $22.21M |
| Long-term Debt | $94.42M | $95.78M | $97.13M | $98.49M | $99.85M | $101.20M | $102.55M | $103.91M | $105.27M | $106.63M |
| Total Liabilities | $136.99M | $158.01M | $176.79M | $183.64M | $208.21M | $224.57M | $228.08M | $234.55M | $205.01M | $191.84M |
| Stockholders' Equity | ($56.09M) | ($58.54M) | ($72.75M) | ($85.10M) | ($89.98M) | ($105.93M) | ($130.34M) | ($143.34M) | ($35.40M) | ($29.40M) |
| Retained Earnings | ($46.03M) | ($49.55M) | ($63.76M) | ($79.48M) | ($84.35M) | ($100.30M) | ($124.72M) | ($137.72M) | ($31.30M) | ($29.39M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.90M | - | - | - | $6.47M | - | - | - | $7.37M | - |
| Investing Cash Flow | ($1.17M) | - | - | - | ($1.85M) | - | - | - | ($12.18M) | - |
| Financing Cash Flow | ($21.54M) | - | - | - | ($2.26M) | - | - | - | ($5.41M) | - |
| CapEx | $362.0K | - | - | - | $1.63M | - | - | - | $704.0K | - |
| Free Cash Flow | $3.54M | - | - | - | $4.84M | - | - | - | $6.67M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 7.0% | - | 17.2% | 22.0% | 19.8% | - | 23.7% | 12.7% | 22.3% | - |
| EBITDA margin | 9.2% | - | - | - | 21.5% | - | 24.1% | 13.1% | 23.9% | - |
| Net margin | 5.1% | - | 17.1% | 6.5% | 28.0% | - | 20.8% | -12.9% | -4.4% | - |
| Free cash flow margin | 7.9% | - | - | - | 9.9% | - | - | - | 14.2% | - |
| FCF / Net income | 1.55 | - | - | - | 0.35 | - | - | - | -3.22 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 61.8% | - | 54.5% | 49.6% | 54.5% | - | 46.8% | 56.2% | 49.2% | - |
| Effective tax rate | 22.5% | - | -10.3% | 40.3% | 10.5% | - | 23.0% | - | 597.6% | - |
| Return on assets | 2.6% | - | 7.4% | 3.0% | 11.1% | - | 10.6% | -6.8% | -1.3% | - |
| Return on equity | -4.1% | - | -11.3% | -3.7% | -15.2% | - | -8.2% | 4.4% | 5.8% | - |
| Return on invested capital | 6.4% | - | 33.9% | 48.0% | 87.9% | - | - | - | 7.5% | - |
| Liquidity | ||||||||||
| Current ratio | 1.29 | 1.22 | 1.01 | 0.98 | 1.42 | 1.32 | 1.50 | 1.34 | 4.75 | 5.51 |
| Quick ratio | 0.58 | 0.79 | 0.72 | 0.74 | 1.14 | 1.03 | 1.16 | 0.92 | 3.97 | 4.73 |
| Cash ratio | 0.19 | 0.54 | 0.50 | 0.39 | 0.86 | 0.76 | 0.82 | 0.57 | 3.28 | 4.01 |
| Leverage | ||||||||||
| Debt / Equity | -1.68 | -1.64 | -1.34 | -1.16 | -1.11 | -0.96 | -0.79 | -0.72 | -2.97 | -3.63 |
| Debt / Assets | 1.06 | 0.89 | 0.87 | 0.94 | 0.81 | 0.83 | 1.01 | 1.12 | 0.66 | 0.69 |
| Debt / EBITDA | 22.77 | - | - | - | 9.47 | - | 8.28 | 16.15 | 9.42 | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -1.59 | -1.84 | -1.53 | -1.23 | -1.37 | -1.16 | -0.78 | -0.65 | -4.52 | -5.28 |
| Liabilities / Assets | 1.54 | 1.47 | 1.59 | 1.75 | 1.69 | 1.84 | 2.25 | 2.52 | 1.28 | 1.24 |
| Efficiency | ||||||||||
| Asset turnover | 0.50 | - | 0.43 | 0.47 | 0.40 | - | 0.51 | 0.53 | 0.29 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 60d | - | 61d | 68d | 58d | - | 60d | 57d | 63d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 22.5x | - | 13.6x | 40.2x | 9.0x | - | 16.9x | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 1.1x | - | 2.3x | 2.6x | 2.5x | - | 3.5x | 5.0x | 4.3x | - |
| EV / EBITDA | 33.2x | - | - | - | 17.2x | - | 19.7x | 50.4x | 20.3x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -8.3% | - | -6.7% | -0.6% | 4.7% | - | 12.8% | -0.2% | 4.4% | - |
| Revenue CAGR (3y) | 0.1% | - | 4.5% | 12.0% | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -67.3% | - | -32.1% | 72.7% | -7.1% | - | 60.3% | -18.7% | 32.3% | - |
| Net income growth (YoY) | -83.4% | - | -23.5% | - | - | - | 42.1% | -22.9% | 69.6% | - |
| EPS growth (YoY) | -83.8% | - | -33.3% | - | - | - | 37.5% | 24.0% | 84.6% | - |
| EPS CAGR (3y) | - | - | - | -63.2% | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -26.8% | - | - | - | -27.5% | - | - | - | -47.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 37.7% | 44.7% | 44.2% | 40.6% | -154.2% | -260.3% | -221.6% | -208.9% | 27.1% | 33.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$384.44M totalProduct Revenue$186.92M · 48.6%
Pellet Procedures Product Revenue$137.04M · 35.6%
Dietary Supplements$42.88M · 11.2%
Service Revenue$5.29M · 1.4%
Disposable Trocars Product Revenue$4.85M · 1.3%
Other Service Revenue$2.86M · 0.7%
Shipping Fees And Other Product Revenue$2.15M · 0.6%
Contract Term Services Revenue$1.36M · 0.4%
Training Service Revenue$1.08M · 0.3%
Geographic
$191.20M totalUS$191.20M · 100.0%
Peer comparison
Same SIC group: Medicinal Chemicals & Botanical Products
Comparing biote Corp. against the 5 most active filers in the same SIC group.